Philip Mease, MD: Upadacitinib Showing Promise Treating Psoriatic Arthritis

June 7, 2020
Kenny Walter

Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

Dr. Philip Mease explains the relationship between rheumatoid arthritis and psoriatic arthritis.

Upadacitinib, already a proven and effective treatment for rheumatoid arthritis, could also be an effective treatment for psoriatic arthritis.

In data planned for presentation during the European Congress of Rheumatology (EULAR) 2020 meeting, a team of researchers assessed the efficacy and safety of upadacitinib compared to placebo in patients with psoriatic arthritis with prior inadequate response or intolerance to at least 1 biologic disease-modifying anti-rheumatic drug (bDMARD).

In the SELECT-PsA-2 trial, 641 patients were equally randomized to receive upadacitinib 15 mg (UPA15), 30 mg (UPA30), or placebo. The investigators stratified patients by baseline biologic disease-modifying anti-rheumatic drug use, number of failed attempts, and extent of psoriasis.

Overall, a significantly greater proportion receiving either dosage of upadacitinib compared to placebo achieved ACR20 at week 12 (56.9% and 63.8% vs 24.1%; P < .0001 for both comparisons).

The investigators observed statistically significant improvements in both upadacitinib treatment arms compared to placebo in all multiplicity controlled secondary endpoints including ΔHAQ-DI (PBO, -0.10; UPA15, -0.30; UPA30, -0.41), ΔSF-36 PCS (PBO, 1.6; UPA15, 5.2; UPA30, 7.1), ΔFACIT-F (PBO, 1.3; UPA15, 5.0; UPA30, 6.1), and ΔSAPS (PBO, -1.5; UPA15, -24.4; UPA30, -29.7; P < .0001 for all endpoints).

In an interview with HCPLive®, Philip J. Mease, MD, director of rheumatology research at the Swedish Rheumatology Research Group, explained the positive upadacitinib results and how intertwined rheumatoid arthritis is with psoriatic arthritis.


x